FoxO1 as a tissue-specific therapeutic target for type 2 diabetes

Area of Science:

• Endocrinology
• Molecular Biology
• Metabolic Diseases

Background:

• Forkhead box O (FoxO) proteins, particularly FoxO1, are key transcription factors regulating physiological processes.
• FoxO1's role in metabolism is extensively studied, with emerging debate regarding its therapeutic potential for type 2 diabetes mellitus (T2D).
• Contradictory findings exist regarding FoxO1's impact on T2D, with effects varying by tissue type and cellular context.

Purpose of the Study:

• To review the multifaceted actions of FoxO1 in metabolic tissues relevant to T2D.
• To highlight current therapeutic strategies targeting FoxO1 for T2D treatment.
• To reconcile conflicting data on FoxO1's role in diabetes pathology and progression.

Main Methods:

• Literature review of studies investigating FoxO1 in metabolic tissues.
• Analysis of FoxO1's effects on glucose and lipid metabolism.
• Examination of FoxO1's influence on insulin secretion and neurodegenerative disease comorbidities.

Main Results:

• FoxO1 activity contributes to T2D pathology in some tissues (e.g., increased hepatic glucose production).
• Opposing effects of FoxO1 were observed in hepatic lipogenesis, adipogenesis, and pancreatic insulin secretion.
• FoxO1 influences skeletal muscle metabolism and has implications for neurodegenerative diseases like Alzheimer's and Parkinson's.

Conclusions:

• FoxO1 exhibits tissue-specific and context-dependent roles in T2D.
• Targeting FoxO1 presents a complex therapeutic challenge due to its dual actions.
• Further research is needed to fully elucidate FoxO1's role and optimize its therapeutic targeting for T2D.